microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification.

Stamatopoulos, Basile;Meuleman, Nathalie;Haibe-Kains, Benjamin;Saussoy, Pascale;Lagneaux, Laurence;et.al.
(2009) Blood — Vol. 113, n° 21, p. 5237-5245 (2009)

Files

No attached file found for this publication.

Details

Authors
  • Stamatopoulos, Basile
    Author
  • Meuleman, Nathalie
    Author
  • Haibe-Kains, Benjamin
    Author
  • Author
  • Author
  • Michaux, LucienneUCLouvain
    Author
  • Lagneaux, Laurence
    Author
Show more
Abstract
Aberrant expression of microRNAs has been recently associated with chronic lymphocytic leukemia (CLL) outcome. Although disease evolution can be predicted by several prognostic factors, a better outcome individualization in a given patient is still of utmost interest. Here, we showed that miR-29c and miR-223 expression levels decreased significantly with progression from Binet stage A to C were significantly lower in poor prognostic subgroups (defined by several prognostic factors) and could significantly predict treatment-free survival (TFS) and overall survival (OS). Furthermore, we developed a quantitative real-time polymerase chain reaction (qPCR) score combining miR-29c, miR-223, ZAP70, and LPL (from 0 to 4 poor prognostic markers) to stratify treatment and death risk in a cohort of 110 patients with a median follow-up of 72 months (range, 2-312). Patients with a score of 0/4, 1/4, 2/4, 3/4, and 4/4 had a median TFS of greater than 312, of 129, 80, 36, and 19 months, respectively (hazard ratio, HR(0/4 < 1/4 < 2/4 < 3/4 < 4/4) = 17.00, P < .001). Patients with a score of 0-1/4, 2-3/4, and 4/4 had a median OS of greater than 312, of 183 and 106 months, respectively (HR(0/4 < 1/4 < 2/4 < 3/4 < 4/4) = 13.69, P = .001). This score will help to identify, among the good and poor prognosis subgroups, patients who will need early therapy and thus will require a closer follow-up.
Affiliations

Citations

Stamatopoulos, B., Meuleman, N., Haibe-Kains, B., Saussoy, P., Van Den Neste, E., Michaux, L., Heimann, P., Martiat, P., Bron, D., & Lagneaux, L. (2009). microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood, 113(21), 5237-5245. https://doi.org/10.1182/blood-2008-11-189407 (Original work published 2009)